Improving Access to Innovative Cancer Therapies in Canada
Date held: April 5, 2018
Presented by: Robin Markowitz (CEO) and Elizabeth Lye (Scientific Advisor) from Lymphoma Canada
The CCSN webinar series is of interest to patients, survivors, family, friends, caregivers, and any member of the community interested in the best possible care and follow-up for cancer patients and survivors. The impact of volunteering and taking positive action to effect change are important elements in the transition to post-treatment life.
Robin Markowitz and Elizabeth Lye from Lymphoma Canada discussed recent pCODR drug funding requests for innovative cancer therapies and how negative funding recommendations are affecting patient access to effective new treatments. To read the white paper discussed in this webinar, visit our website: http://bit.ly/2q8duxM
Bringing Rare Disease Drugs to Canada Opportunities, Challenges, and More Challenges
Date held: March 21, 2018
Presented by: Bill Dempster of 3Sixty Public Affairs
This webinar was an interactive live webcast from the Canadian Organization for Rare Disorders’ Rare Disease Day event in Ottawa.
The session was moderated by 3Sixty Public Affairs’ Bill Dempster, who was joined by several Canadian experts in pharmaceutical access, including a former director of the Ontario Public Drug Programs. This discussion reviewed the current state of public reimbursement for orphan medicines and examined how the emerging discussions about a new national pharmacare program will affect patient access to these medicines.
The session was followed by an interactive question and answer session.
Anal & Colorectal Cancer
Date held: March 8, 2018
Presented by: Helene Hutchings of Anal Cancer: A Bum Rap
CCSN welcomed back Helene Hutchings to discuss anal and colorectal cancer in this educational webinar. Helene discussed the symptoms & risk factors of these cancers, as well as treatment options that are available. She also discussed prevention of anal and colorectal cancers and the benefits of peer-to-peer support groups.
The importance of clinician engagement in the HTA process
Date held: January 23, 2018
Presented by: Bill Dempster with Alexandra Chambers & Dr. Craig Earle
Join Alexandra Chambers & oncologist Dr. Craig Earle with CADTH’s pan-Canadian Oncology Drug Review (pCODR) as they discuss the opportunities for clinicians to participate in the process and be part of the system, and how clinician input can help to inform cancer drug funding recommendations to enhance patient outcomes for Canadians. 3Sixty Public Affairs’ Bill Dempster moderated this interactive webinar that included opportunities for participants to participate in polling and ask questions.
Federal pharmaceutical pricing reform: What do patients think?
Date held: January 18, 2018
Presented by: Bill Dempster with Louise Binder & Martine Elias
Bill Dempster & guests Louise Binder & Martine Elias discussed the updates to the federal pharmaceutical price reform proposal, how patient leaders are responding and what steps they are taking to ensure that patients are being heard by decision makers.